Chronic pain affects roughly 51 million adults in the United States alone, and for most of them, the available drug options remain blunt instruments: opioids that carry addiction risk, or anti-inflammatories that barely dent nerve-driven pain. A study published in April 2026 in Nature Communications now offers a sharper view of the problem. Researchers have built the first protein-level atlas of pain-sensing neurons in mice, cataloging more than 6,000 proteins across distinct nociceptor subtypes and flagging a set of enzymes that could become targets for a new generation of non-opioid painkillers.
Why proteins, not just genes
Scientists have classified pain-sensing neurons by their gene activity for over a decade. A landmark 2015 study in Nature Neuroscience used single-cell RNA sequencing to sort mouse sensory neurons into distinct subtypes, including the two major classes of nociceptors: peptidergic neurons, which release inflammatory signaling molecules, and non-peptidergic neurons, which rely on different surface receptors and ion channels.
But RNA is only a blueprint. The proteins a cell actually produces, and how many of each it keeps on hand, determine what that cell does. The new study’s central argument is that gene-expression snapshots miss functional differences that only show up when you measure the proteins directly.
To do that, the team used a technique called Deep Visual Proteomics, first described in a 2022 paper in Nature Biotechnology. The method pairs AI-guided microscopy with ultra-sensitive mass spectrometry, allowing researchers to measure thousands of proteins from small, precisely selected groups of cells. Critically, the team inverted the usual workflow: they first used functional imaging and electrophysiology to classify mouse dorsal root ganglion neurons by how they respond to stimuli like heat and capsaicin, then applied proteomics to those functionally defined cells. That sequence helps ensure the molecular signatures correspond to real pain-relevant subtypes rather than statistical clusters.
What the atlas shows
The resulting map confirmed known subtype markers and revealed new ones. Peptidergic nociceptors were enriched for neuropeptides tied to inflammatory signaling; non-peptidergic neurons carried distinct surface receptors and structural proteins. Many of these protein-level differences had not been predicted by earlier RNA data.
The more striking results came from a sensitization experiment. The researchers exposed nociceptors to nerve growth factor (NGF), a molecule the body releases during tissue inflammation that is known to amplify pain signals. After NGF treatment, coordinated shifts appeared across signaling enzymes, kinases, and cytoskeletal regulators. Those changes, reproducible across biological replicates, point to specific molecular pathways that may govern the transition from short-lived pain to the persistent kind.
The raw mass spectrometry data are publicly available in the PRIDE archive under identifier PXD070495, meaning any lab in the world can reanalyze the spectra to verify the protein counts and the NGF-driven shifts. That transparency is notable: it invites independent scrutiny rather than requiring readers to take the authors’ word for it.
The anti-NGF backstory
NGF is not a new name in pain medicine. Pharmaceutical companies have spent years developing monoclonal antibodies that neutralize NGF itself. Tanezumab, developed by Pfizer and Eli Lilly, reached late-stage clinical trials for osteoarthritis and chronic low back pain but ran into safety concerns, including reports of rapidly progressing joint destruction in some patients. The U.S. Food and Drug Administration has not approved it.
That history is directly relevant. Blocking NGF wholesale turned out to be too crude: the molecule plays roles in joint maintenance and nerve survival that you do not want to shut down entirely. The new proteomic data suggest a more surgical approach. Instead of neutralizing NGF at the top of the cascade, it may be possible to target the specific downstream enzymes that NGF activates inside nociceptors, potentially preserving the molecule’s protective functions while still interrupting pain amplification.
Where the gaps are
The entire dataset comes from mice. A study in the journal PAIN that directly compared human and mouse sensory neurons at the transcriptomic level found meaningful cross-species differences, particularly in how drug targets are expressed in lab-cultured cells versus living tissue. Enzymes that look promising in mouse proteomes may not hold the same role in human pain circuits.
No behavioral pain data accompany the proteomic results. The study identifies candidate targets through changes in protein abundance after NGF exposure, but it does not test whether blocking those targets actually reduces pain in animals. That step, typically involving knockout models or selective inhibitors in rodent pain assays, is the standard next hurdle before any target can attract serious pharmaceutical investment.
There are also questions of scope. NGF is a well-established driver of inflammatory pain, but chronic pain in humans arises from many sources: nerve injury, chemotherapy, diabetes, and changes in the central nervous system itself. Whether the same protein-level switches highlighted here are engaged in those other pain types remains unknown.
On the technical side, Deep Visual Proteomics still involves trade-offs. Very low-abundance proteins, including some transcription factors and signaling molecules, may fall below detection thresholds. Post-translational modifications, which can dramatically alter protein function without changing abundance, are only partially captured. The atlas is detailed but not exhaustive.
What comes next for pain research
The immediate value of this work is as a reference resource. For the first time, pain researchers can look up how thousands of proteins are distributed across functionally defined nociceptor subtypes and see exactly which ones shift when inflammatory signaling kicks in. That catalog can be cross-referenced against databases of druggable protein families, giving drug developers a prioritized list of candidates to test.
For basic scientists, the atlas reopens questions about nociceptor diversity. By comparing protein profiles with earlier RNA-based classifications, researchers can now ask which subtype distinctions are primarily transcriptional and which are enforced at the level of protein stability or trafficking. Those insights could reshape how future studies design genetic tools, choose markers for cell sorting, or interpret changes in pain behavior after experimental manipulations.
But the distance between a proteomic hit list and a pill that helps patients is measured in years and marked by frequent failure. Target validation, selectivity screening, structure-based drug design, and safety testing each represent major hurdles, and many promising molecular leads do not survive them. The new neuron map sharpens the picture of how pain-sensing neurons are built and how they respond to a key inflammatory cue. Whether any of the enzymes it highlights will eventually underpin safer painkillers depends on a long chain of experiments that is only now getting started.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
